Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Cerebrovascular Accident
Interventions: Magnesium Sulfate, Normal Saline; Drug
Lead sponsor: Jeffrey L. Saver; Other
Eligibility: 40 Years to 95 Years
Enrollment: 1,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hernia, Inguinal, Post Operative Pain
Interventions: local anaesthetic injection of CPL-01, Morphine (rescue medication), Acetaminophen (rescue medication), Oxycodone (rescue medication), local anaesthetic injection of placebo, local anaesthetic injection of ropivacaine HCl, Open inguinal hernia repair; Drug · Procedure
Lead sponsor: Cali Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
Interventions: Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL), Infants in the control group (S/P group) receive placebo (Normal saline 1mL); Drug
Lead sponsor: University of Arizona; Other
Eligibility: Up to 18 Hours
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone
Interventions: Hydrocortisone, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Transplantation, Mesenchymal Stem Cells
Interventions: Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion; Biological · Other
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COPD Exacerbation
Interventions: Formoterol, Placebo; Drug · Other
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: University of Oxford; Other
Eligibility: 40 Years and older
Enrollment: 16,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2049
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Surgical Site Infection
Interventions: ZuraPrep with 70% IPA, ZuraPrep without 70% IPA, ChloraPrep CHG/IPA Teal Tint, Normal Saline; Drug · Other
Lead sponsor: Zurex Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Sterling, Virginia

Conditions: Amputation, Phantom Limb, Stump Pain
Interventions: perineural ropivacaine, normal saline (placebo); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Kidney Injury
Interventions: 0.9% Sodium Chloride (Placebo), Sodium Bicarbonate; Drug
Lead sponsor: Community Medical Center, Scranton, PA; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Aortic Arch Hypoplasia or Interruption
Interventions: Erythropoetin, Normal saline; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Day to 30 Days
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: ARINA-1, Placebo; Drug
Lead sponsor: Renovion, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Pain, Postoperative
Interventions: Nasal Nicotine Spray, Nasal Normal Saline Spray; Drug
Lead sponsor: Toby Weingarten; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Respiratory Distress Syndrome (ARDS), Acute Lung Injury (ALI)
Interventions: methylprednisolone, Normal Saline (0.9%); Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 1 Month to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cardiac Diseases
Interventions: 5% albumin, crystalloid; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 1 Day to 36 Months
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gingivitis
Interventions: Silver Diamine Fluoride, Normal Saline; Device · Other
Lead sponsor: Texas A & M University Baylor College Of Dentistry; Other
Eligibility: 65 Years to 90 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Nephrectomy, Partial Nephrectomy, Incision Site Discomfort
Interventions: Ropivacaine, Normal saline; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Anemia, Sickle Cell
Interventions: SANGUINATE, Placebo; Drug
Lead sponsor: Prolong Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Hollywood, Florida • Tampa, Florida • Baltimore, Maryland + 5 more

Conditions: Polytrauma
Interventions: Ketorolac, Saline Solution; Drug
Lead sponsor: Arun Aneja; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Lower Eyelid Steatoblepharon
Interventions: POLAT-001, Placebo; Drug
Lead sponsor: Peregrine Ophthalmic; Industry
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Newport Beach, California • Coral Gables, Florida • Pflugerville, Texas

Conditions: Painful Diabetic Neuropathies
Interventions: Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline); Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more

Conditions: Pain, Postoperative
Interventions: Liposomal Bupivacaine, 0.25% Bupivacaine with epinephrine, Saline; Drug
Lead sponsor: American Hip Institute; Other
Eligibility: 18 Years to 90 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Hinsdale, Illinois • Westmont, Illinois

Conditions: Pre-Eclampsia
Interventions: Human Albumin (colloid), Lactated Ringer's Injection (crystalloid), Edwards HemoSphere monitor with ClearSight-Acumen finger cuff; Drug · Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Degenerative Disc Disease
Interventions: IDCT, Saline Solution, Sodium Hyaluronate; Biological · Drug
Lead sponsor: DiscGenics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more

Search by objective public record fields.

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

Herniorrhaphy for Postoperative Pain

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

Corticosteroids to Treat Pancreatitis

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle

Naval Medical Center San Diego (NMCSD) - Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain

Prevention of Acute Kidney Injury in Cardiac Surgery Patients

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Nicotine Administration and Post-operative Opioid Use With Bariatric Surgery

Trial of Steroids in Pediatric Acute Lung Injury/ARDS

The Use of Colloid Versus Crystalloid in Post-operative Pediatric Cardiac Patients for Fluid Resuscitation

Silver Diamine Fluoride and Gingivitis in Geriatric Patients

Erector Spinae Plane Block (ESPB): in Patients Undergoing Surgery Through a Flank or Anterior Subcostal Incision.

Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis

Inflammatory Markers in Trauma Patient Outcomes

Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

Intraoperative Liposomal Bupivacaine vs. Bupivacaine for Total Hip Replacement Pain Management

Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration